ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion.

The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

NCT00596999

Hematologic Malignancies

UNKNOWN

Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies

NCT00513318

Acute Myeloid Leukemia Myelodysplasia Acute Lymphoblastic Leukemia +4 more

TERMINATED

Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders

NCT00897260

Hematological Malignancy Bone Marrow Failure Syndrome

COMPLETED NA

Intrabone Cord Blood Transplantation

NCT00838019

Hematological Malignancies

UNKNOWN PHASE4

Cord Blood Stem Cell Transplantation Study (COBLT)

NCT00000603

Anemia, Aplastic Fanconi Anemia Hematologic Diseases +5 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the child's normal cells including their bone marrow (which forms blood cells) in order to prepare their body for the umbilical cord blood transplant. The cord blood transplant is intended to rescue your child's bone marrow from the bad effects of the procedure. The child will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell called ALD-101.

The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly after transplant. This would shorten the period of time that the transplanted subject would be at risk for infection and bleeding and would also decrease the number of red blood cell and platelet transfusions needed.

ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with genetic diseases and malignancy in one previous clinical study that is on-going.

The main purpose of this research study is to test whether a portion of cord blood cells that have been separated from a cord blood unit (ALD-101) will increase the speed at which normal levels of circulating blood cells are re-established after transplant. This is the experimental part of this study. ALD-101 is also being tested to see if it is safe.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inherited Metabolic Diseases Lysosomal Storage Disorders Peroxisomal Storage Diseases Inborn Errors of Metabolism Mucopolysaccharidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

Group Type EXPERIMENTAL

ALD-101

Intervention Type BIOLOGICAL

A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALD-101

A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed diagnosis of inherited metabolic diseases; including the following:

* Hurler Syndrome (MPS I)
* Hurler-Scheie Syndrome
* Hunter Syndrome (MPS II)
* Sanfilippo Syndrome A and B(MPS III)
* Maroteaux-Lamy Syndrome (MPS VI)
* Krabbe Disease (Globoid Leukodystrophy)
* Metachromatic Leukodystrophy (MLD)
* Adrenoleukodystrophy (ALD and AMN)
* Sandhoff Disease
* Tay Sachs Disease
* Pelizaeus Merzbacher (PMD)
* Niemann-Pick Disease
* Alpha-mannosidosis
* I-Cell Disease (ML II)
* Fucosidosis
* GM I Gangliosidosis
* Canavan Disease
* must be \<16 years of age at the time of study enrollment
* must have a good performance status (Lansky ≥80%)
* must have adequate function of other organ systems including: kidney, liver, heart and lungs
* must have given valid written informed consent
* must have a minimum life expectancy of at least 6 months
* must be determined to be a good candidate for a standard umbilical cord blood transplant
* must have an IQ \>70 or if too young for IQ testing the potential to reach this endpoint by age 5

Exclusion Criteria

* HIV, Hepatitis B and/or Hepatitis C positive
* concurrently involved in any other clinical study that affects engraftment or immune reconstitution
* uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain stem involvement
* uncontrolled infections
* prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12 months of enrollment

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No